Paul Jeng
Stock Analyst at Guggenheim
(2.89)
# 1,716
Out of 5,090 analysts
6
Total ratings
100%
Success rate
21.67%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Paul Jeng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADAG Adagene | Initiates: Buy | $9 | $1.99 | +352.26% | 1 | Nov 24, 2025 | |
| IMTX Immatics | Maintains: Buy | $16 → $19 | $10.18 | +86.64% | 2 | Nov 18, 2025 | |
| IMCR Immunocore Holdings | Assumes: Neutral | n/a | $38.78 | - | 1 | Sep 18, 2025 | |
| CNTX Context Therapeutics | Initiates: Buy | $5 | $1.05 | +376.19% | 1 | Sep 18, 2025 | |
| IDYA IDEAYA Biosciences | Initiates: Buy | $50 | $35.87 | +39.39% | 1 | Sep 18, 2025 |
Adagene
Nov 24, 2025
Initiates: Buy
Price Target: $9
Current: $1.99
Upside: +352.26%
Immatics
Nov 18, 2025
Maintains: Buy
Price Target: $16 → $19
Current: $10.18
Upside: +86.64%
Immunocore Holdings
Sep 18, 2025
Assumes: Neutral
Price Target: n/a
Current: $38.78
Upside: -
Context Therapeutics
Sep 18, 2025
Initiates: Buy
Price Target: $5
Current: $1.05
Upside: +376.19%
IDEAYA Biosciences
Sep 18, 2025
Initiates: Buy
Price Target: $50
Current: $35.87
Upside: +39.39%